Trial Profile

A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Narsoplimab (Primary)
Indications Atypical Haemolytic Uraemic Syndrome
Focus Registrational; Therapeutic Use
Sponsors Omeros Corporation

Most Recent Events

08 May 2023 The trial has been completed in Lithuania, according to European Clinical Trials Database record.
24 Dec 2022 The trial has been completed in Poland, according to European Clinical Trials Database record.
08 Sep 2016 Status changed from not yet recruiting to recruiting, as reported by an Omeros Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com